Lesedauer von 4 Min.
20. Mai 2025
Lesedauer von 2 Min.
28. April 2025
Lesedauer von 4 Min.
09. April 2025
Lesedauer von 4 Min.
09. September 2025
Artikel
Accurate, timely diagnosis is central to limiting the clinical and operational impact of seasonal and emerging respiratory viruses.
During a recent webinar, Scott Sugden, Ph.D., Sr. Director of Medical Affairs, Canada at Cepheid, reviewed the strengths of PCR-based molecular testing compared to antigen testing and explained why moving molecular testing to the point of care (POC) can amplify those advantages. Below are some highlights from the presentation.
Dr. Sugden addressed the fact that sensitivity differences in testing methods for respiratory viruses translate into missed cases when viral load is low early in infection, which in turn can lead to missed opportunities for antiviral therapies and effective transmission prevention techniques.
Greater sensitivity only benefits patients if the results arrive before treatment or infection-control decisions are made. Dr. Sugden highlighted POC PCR as a way to compress turnaround from days to minutes. He reviewed several studies showing important clinical impacts of onsite and POC testing.
Dr. Sugden noted that cost-per-test is only part of the economic picture; delayed or inaccurate results carry hidden expenses, including equipment and staff time. A few hard numbers he shared:
These highlights provide an overview of the evidence Dr Sugden presented. Watch the on-demand webinar to explore the underlying studies and implementation tips in greater detail.
Literatur
MEHR